Engineered immune cells take aim at stubborn lymphoma

NCT ID NCT07162012

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, engineering them to recognize and attack EBV-infected cancer cells, and infusing them back. The study will enroll 24 participants to find the safest dose and watch for early signs of benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-EBV autologous TCR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat EBV-positive lymphomas.
What could go wrong: This is a very early, small trial (24 people) focused on safety and dosing. The treatment may not work or could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Epstein-Barr virus-associated lymphoproliferative disorder Epstein-Barr virus-related tumor Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL NK/T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA (PTCL)

Contacts and locations

Locations

Shanghai General Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.